^aThe UC-CARES study was an observational, multinational, multicentre, retrospective chart review including cross-sectional collection of patient-reported outcomes from patients with UC (N=150) carried out in 11 European countries⁵; ^bAnalysis of 10 studies with a total of 3910 participants who received once daily 5-ASA⁸; ^cRetrospective analysis of claims data from the PharMetrics database, which included integrated claims information from 95 managed care health plans spanning all 4 United States Census regions and covering more than 61 million unique patients from 1997 to 2010. 2136 patients were included.⁹